Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC. Hsu PC, et al. Among authors: wang cc. Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20. Target Oncol. 2023. PMID: 36805452 Free PMC article.
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.
Wang CC, Tseng CC, Hsiao CC, Chang HC, Chang LT, Fang WF, Leu S, Wang YH, Tsai TH, Yang CT, Chen CH, Yip HK, Ho CK, Lin MC. Wang CC, et al. Among authors: wang yh. Biomed Res Int. 2014;2014:173401. doi: 10.1155/2014/173401. Epub 2014 Jun 29. Biomed Res Int. 2014. PMID: 25061601 Free PMC article. Clinical Trial.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Chiu CH, et al. Among authors: wang cc. J Thorac Oncol. 2015 May;10(5):793-799. doi: 10.1097/JTO.0000000000000504. J Thorac Oncol. 2015. PMID: 25668120 Free article.
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS, Wang CC, Huang YC, Pavlidis S, Liu CY, Ko HW, Chung FT, Lin TY, Wang CL, Guo YK, Yang CT. Kuo CS, et al. Among authors: wang cc, wang cl. Thorac Cancer. 2019 May;10(5):1158-1166. doi: 10.1111/1759-7714.13057. Epub 2019 Apr 5. Thorac Cancer. 2019. PMID: 30950239 Free PMC article.
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Huang SH, et al. Among authors: wang cc. Thorac Cancer. 2019 Dec;10(12):2274-2281. doi: 10.1111/1759-7714.13221. Epub 2019 Oct 15. Thorac Cancer. 2019. PMID: 31613427 Free PMC article.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Yang JC, et al. Among authors: wang cc, wang z. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. J Thorac Oncol. 2020. PMID: 32916310 Free article. Clinical Trial.
5,237 results